Lexaria Bioscience Corp. (NASDAQ: LEXX) Demonstrates Continued DehydraTECH(TM)-Liraglutide Performance with Ongoing GLP-1 Diabetes Animal Study
Lexaria, a global innovator in drug delivery platforms, is reporting on its eight-week body weight results from its WEIGHT-A24-1 ongoing animal study The study was made up of three main groups of formulations: DehydraTECH-processed CBD; semaglutide (including “Rybelsus(R)”) and liraglutide The DehydraTECH-CBD and DehydraTECH-liraglutide both outperformed Rybelsus(R), which was a surprise outcome. DehydraTECH-liraglutide posted a weight reduction of 4.74%, the most significant in the study For Lexaria, this continued outperformance of DehydraTECH-liraglutide is of particular interest, particularly since many third-party studies have shown semaglutide to be more than twice as effective as liraglutide in promoting weight loss As the study…
